




IN THE OFFICE
UNITED STATES PATENT AND TRADEMARK OFFICE

41
A
pg
10-11-01

Applicant: Mary Faris et al. Examiner: Not yet assigned
Serial No.: 09/809,638 Group Art Unit: 1645
Filed: March 14, 2001 Docket: G&C 129.35-US-01
Title: 125P5C8: A TISSUE SPECIFIC PROTEIN HIGHLY EXPRESSED IN
VARIOUS CANCERS

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on July 30, 2001.

By: 
Name: Karen S. Canady

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to a first Office Action, please amend the above-identified application as follows. Please note that in compliance with the new rules under 37 C.F.R. § 1.121 the amendments to the specification are presented in "clean" form with a marked-up version provided in the Appendix.

IN THE SPECIFICATION

Please amend the specification as follows:

Please replace the paragraphs at page 3, lines 11-¹⁷~~18~~, with the following paragraphs:

ya 3/7/07

A'
Figure 1. 125P5C8 SSH sequence (SEQ ID NO: 3). The SSH experiment was performed with cDNA digested with DPN II. The 125P5C8 sequence contains 287 bp.

Figure 2. The cDNA (SEQ ID NO: 1) and amino acid (SEQ ID NO: 2) sequence of 125P5C8.